IL150209A0 - Method of decreasing fasting sugars and weight gains in diabetic patients - Google Patents

Method of decreasing fasting sugars and weight gains in diabetic patients

Info

Publication number
IL150209A0
IL150209A0 IL15020902A IL15020902A IL150209A0 IL 150209 A0 IL150209 A0 IL 150209A0 IL 15020902 A IL15020902 A IL 15020902A IL 15020902 A IL15020902 A IL 15020902A IL 150209 A0 IL150209 A0 IL 150209A0
Authority
IL
Israel
Prior art keywords
diabetic patients
weight gains
decreasing fasting
sugars
fasting sugars
Prior art date
Application number
IL15020902A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL150209A0 publication Critical patent/IL150209A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15020902A 2001-06-21 2002-06-12 Method of decreasing fasting sugars and weight gains in diabetic patients IL150209A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30004901P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
IL150209A0 true IL150209A0 (en) 2002-12-01

Family

ID=23157477

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15020902A IL150209A0 (en) 2001-06-21 2002-06-12 Method of decreasing fasting sugars and weight gains in diabetic patients

Country Status (15)

Country Link
US (2) US20030079747A1 (cs)
EP (1) EP1270012A1 (cs)
JP (1) JP2003012543A (cs)
KR (1) KR20020097033A (cs)
CN (1) CN1289143C (cs)
AU (1) AU4884102A (cs)
CA (1) CA2390757A1 (cs)
CZ (1) CZ20022151A3 (cs)
HK (1) HK1049617B (cs)
HU (1) HUP0202042A3 (cs)
IL (1) IL150209A0 (cs)
NZ (1) NZ519403A (cs)
PL (1) PL354641A1 (cs)
SK (1) SK9042002A3 (cs)
ZA (1) ZA200204859B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054606A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Method of decreasing hepatic glucose output in diabetic patients
AR046485A1 (es) * 2003-03-04 2005-12-14 Technology Dev Company Ltd Sistema de administracion para drogas y terapia celular
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
EP2060268A1 (en) * 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
US20120108947A1 (en) * 2009-07-22 2012-05-03 Eli Lilly And Company Method for predicting weight gain associated with a pharmaceutical therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK0592540T3 (da) * 1991-07-02 2000-06-26 Inhale Inc Fremgangsmåde og indretning til aflevering af aerosoliserede medikamenter
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5743250A (en) * 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CA2183577C (en) * 1994-03-07 2007-10-30 John S. Patton Methods and compositions for pulmonary delivery of insulin
CA2606600C (en) * 1994-09-21 2009-09-01 Nektar Therapeutics Apparatus and methods for dispersing dry powder medicaments
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
DE69920767T2 (de) * 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
JP2002543092A (ja) * 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
WO2001000674A1 (en) * 1999-06-29 2001-01-04 Eli Lilly And Company Insulin crystals for pulmonary administration
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CN100384430C (zh) * 2001-04-04 2008-04-30 奥索-麦克尼尔药品公司 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗
GEP20063917B (en) * 2001-05-21 2006-09-11 Nektar Therapeutics Pulmonary administration of chemically modified insulin

Also Published As

Publication number Publication date
CA2390757A1 (en) 2002-12-21
ZA200204859B (en) 2004-01-28
JP2003012543A (ja) 2003-01-15
NZ519403A (en) 2005-03-24
CN1289143C (zh) 2006-12-13
HK1049617A1 (en) 2003-05-23
HU0202042D0 (cs) 2002-08-28
US20030079747A1 (en) 2003-05-01
SK9042002A3 (en) 2003-05-02
HUP0202042A2 (hu) 2004-05-28
US20050220722A1 (en) 2005-10-06
PL354641A1 (en) 2002-12-30
EP1270012A1 (en) 2003-01-02
HK1049617B (zh) 2007-03-16
HUP0202042A3 (en) 2004-06-28
CZ20022151A3 (cs) 2003-04-16
AU4884102A (en) 2003-01-02
KR20020097033A (ko) 2002-12-31
CN1393265A (zh) 2003-01-29

Similar Documents

Publication Publication Date Title
AU2001282550A1 (en) Method of quantifying total hemoglobin and glycohemoglobin
AU2001298042A1 (en) Optimized pulsatile-flow ventricular-assist device and total artificial heart
AU2002310076A1 (en) Structure and method to preserve sti during etching
AUPR733901A0 (en) Method and means of physiological monitoring
AU2002345328A1 (en) Method and device for electrochemical formation of therapeutic species in vivo
AU2003267250A1 (en) Continuous heart valve support frame and method of manufacture
SG87194A1 (en) Lead frame and method of manufacturing the lead frame
AU2003235403A8 (en) Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
IL164400A0 (en) Deruvatuves if n-Äphenyl(piperidin-2-yl)methylÜbenzamide, the preparation method thereof and application of same in therapeutics
AU2003214775A1 (en) Physiologically compatible cardiac assist device and method
AU2003288517A1 (en) In vivo imaging device and method of manufacture thereof
IL166882A (en) Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
IL160835A0 (en) Catheter and method of using same
AU2002367023A1 (en) Compositions and methods for treating heart failure
PL339486A1 (en) Novel compounds - substituted 3-amino-3-aryl 1-propanols and method of obtaining them as well as therapeutic agent and method of obtaining same
AU2002365057A1 (en) Compositions and methods for treating heart failure
IL150209A0 (en) Method of decreasing fasting sugars and weight gains in diabetic patients
AU2003224956A1 (en) Reference structures and reference structure enhanced tomography
AU2002366813A8 (en) Cardiac pacing method and system
AU2002246950A1 (en) Hydrocapsules and method of preparation
AU2461801A (en) Interconnect structure and method of fabrication therefor
AU2003276398A8 (en) Shearwall structure and method of making the same
AU2003228787A1 (en) Composition and method for reducing post-prandial blood glucose
PL339487A1 (en) Novel compounds - substituted 3-amino-3-aryl 1-propanols and method of obtaining them as well as therapeutic agent and method of obtaining same
TW501437U (en) Composite structure of computer and frame seat